|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.96 HKD | -5.71% |
|
-0.64% | -33.23% |
| 29/06 | Chinese Biopharma Stocks Rally as Investors Favor Healthcare Over AI | DJ |
| 24/06 | China approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says | RE |
| Market Cap | 11TCr 13TCr 1.59TCr 1.39TCr 1.29TCr 1.18TCr 2.24TCr 1,53700Cr 2.28TCr 15TCr 6.04TCr 75TCr 5.99TCr 5.86TCr 2,59100Cr | P/E 2026 * |
18.4x | P/E 2027 * | 15.2x |
|---|---|---|---|---|---|
| Enterprise Value | 6.83TCr 7.9TCr 1.01TCr 881.02Cr 814.77Cr 747.65Cr 1.42TCr 97TCr 1.44TCr 9.72TCr 3.82TCr 47TCr 3.79TCr 3.7TCr 1,63700Cr | EV / Sales 2026 * |
0.79x | EV / Sales 2027 * | 0.59x |
| Free-Float |
32.24% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: JD Health International Inc.
| 03/02 | Burghley Capital: JD Property Reapplies for HK IPO | AQ |
| 15/24/15 | JD com misses estimates quarterly sales | AQ |
| 16/23/16 | JD.com verslaat verwachtingen | AQ |
| 09/23/09 | JD.com lacks estimates | AQ |
| 01/22/01 | JD Health International : Next Day Disclosure Return | PU |
| 1 day | -5.46% | ||
| 1 week | -0.64% | ||
| Current month | +12.85% | ||
| 1 month | +4.63% | ||
| 3 months | -23.52% | ||
| 6 months | -43.93% | ||
| Current year | -33.23% |
| 1 week | 34.72 |  | 39.7 |
| 1 month | 31.84 | | 39.7 |
| Current year | 31.84 | | 71.7 |
| 1 year | 31.84 | | 71.7 |
| 3 years | 19.48 | | 71.7 |
| 5 years | 19.48 | | 105 |
| 10 years | 19.48 | | 198.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Dong Cao
CEO | Chief Executive Officer | 50 | 29/09/2025 |
Deng Hui
DFI | Director of Finance/CFO | 40 | 11/05/2023 |
Ming King Chiu
SEC | Corporate Secretary | 49 | - |
| Director | Title | Age | Since |
|---|---|---|---|
Qiang Dong Liu
CHM | Chairman | 53 | 14/09/2020 |
Xing Yao Chen
BRD | Director/Board Member | 52 | - |
Ling Li
BRD | Director/Board Member | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 15/05/26 | Other | Company | 6,42,15,503 | 2.0000% | ||
| 31/03/26 | Other | Director | 2,842 | 0.0001% | ||
| 13/10/25 | Other | Director | 3,000 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.71% | -0.64% | -20.90% | -28.52% | 1.53TCr | |
| -3.75% | -4.03% | -28.23% | -33.40% | 692.88Cr | |
| +2.53% | +4.48% | -20.75% | -4.43% | 599.17Cr | |
| -0.14% | +6.41% | -10.33% | -30.02% | 384.28Cr | |
| 0.00% | +9.07% | +11.21% | -29.10% | 323.79Cr | |
| -0.56% | +0.17% | -38.43% | -12.87% | 322.79Cr | |
| -0.11% | -1.03% | -30.04% | -48.44% | 315.19Cr | |
| +1.00% | -1.68% | +94.27% | - | 253.09Cr | |
| +0.33% | +0.33% | -19.84% | -1.40% | 251.64Cr | |
| 0.00% | +0.03% | +3.27% | +35.19% | 170.45Cr | |
| Average | -0.64% | +0.85% | -5.98% | -17.00% | 483.99Cr | |
| Weighted average by Cap. | -1.97% | +0.39% | -13.78% | -22.69% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.66TCr 10TCr 1.28TCr 1.12TCr 1.03TCr 948.59Cr 1.8TCr 1,23200Cr 1.83TCr 12TCr 4.84TCr 60TCr 4.8TCr 4.7TCr 2,07700Cr | 10TCr 12TCr 1.48TCr 1.29TCr 1.19TCr 1.09TCr 2.07TCr 1,42200Cr 2.11TCr 14TCr 5.59TCr 69TCr 5.54TCr 5.42TCr 2,39800Cr |
| Net income | 582.5Cr 674.12Cr 86Cr 75Cr 70Cr 64Cr 120.72Cr 8.29TCr 122.82Cr 829Cr 325.66Cr 4.05TCr 322.93Cr 315.84Cr 14TCr | 706.49Cr 817.61Cr 104.3Cr 91Cr 84Cr 77Cr 146.42Cr 10TCr 148.97Cr 1.01TCr 394.98Cr 4.91TCr 391.67Cr 383.07Cr 17TCr |
| Net Debt | -3.98TCr -4.6TCr -586.98Cr -513.08Cr -474.5Cr -435.41Cr -824.07Cr -57TCr -838.39Cr -5.66TCr -2.22TCr -28TCr -2.2TCr -2.16TCr -95TCr | -4.86TCr -5.62TCr -717.37Cr -627.05Cr -579.9Cr -532.13Cr -1.01TCr -69TCr -1.02TCr -6.92TCr -2.72TCr -34TCr -2.69TCr -2.63TCr -1,16500Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/26/17 | HK$36.96 | -5.71% | 29,22,520 |
| 16/26/16 | HK$39.20 | +4.48% | 1,45,31,390 |
| 15/26/15 | HK$37.52 | +1.52% | 1,00,38,594 |
| 14/26/14 | HK$36.96 | +0.71% | 1,93,18,220 |
| 13/26/13 | HK$36.70 | -1.61% | 1,09,54,031 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 6618 Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition